



ASX Release
8 March 2018

ASX code: PIQ

Proteomics International

LABORATORIES LTD

Secondary Trading Notice

Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) has today issued 1,436,171 fully paid ordinary shares (**Shares**) upon the exercise of quoted options exercisable at \$0.20 per option on or before 31 March 2018 (**PIQO Options**) raising \$287,234.

The issue of Shares on exercise of PIQO Options is exempt from the 15% calculation of the Company's annual placement capacity pursuant to ASX Listing Rule 7.1.

Secondary Trading Notice Pursuant to Paragraph 708A(5)(e) of the Corporations Act 2001 ("Act")

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, a sale of the Shares noted above will fall within the exemption in section 708A(5) of the Act.

The Company hereby notifies ASX under paragraph 708A(5)(e) of the Act that:

- (a) the Company issued the Shares without disclosure to investors under Part 6D.2 of the Act;
- (b) as at the date of this Notice, the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company, and section 674 of the Act; and
- (c) as at the date of this Notice, there is no information:
 - (i) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - (ii) that investors and their professional advisers would reasonably require for the purposes of making an informed assessment of:
 - a. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - b. the rights and liabilities attaching to the relevant Shares.

Proteomics International remains engaged with a number of potential strategic partners to bring the Promarker™ technology to market in Australia and overseas. The Company is also finalising negotiations with potential underwriters of the PIQO Options to take any shortfall that may arise after the expiry date of 31 March 2018. It is possible that announcements may be made in the foreseeable future which could influence the price of PIQ Shares and PIQO Options.

ENDS

For further information please contact:

Karen Logan
Company Secretary
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com